<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609257</url>
  </required_header>
  <id_info>
    <org_study_id>LV03-105</org_study_id>
    <secondary_id>U1111-1177-4095</secondary_id>
    <nct_id>NCT01609257</nct_id>
  </id_info>
  <brief_title>Norovirus Bivalent-Vaccine Efficacy Study</brief_title>
  <official_title>Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety, Immunogenicity, and Efficacy Study in Healthy Adults of Intramuscular Norovirus Bivalent Virus-like Particle Vaccine in Experimental Human Norovirus GII.4 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the norovirus vaccine is effective in
      preventing acute gastroenteritis due to the experimental human Norovirus GII.4 challenge
      dose. The purpose is also to evaluate the safety of the vaccine and the immunogenicity of the
      vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2012</start_date>
  <completion_date type="Actual">March 18, 2014</completion_date>
  <primary_completion_date type="Actual">March 1, 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Viral AGE Clinical Illness and Fecal Virus Excretion Detected by RT-PCR OR 4-Fold Rise In Anti-GII.4 Norovirus P Particle Antibody Titer</measure>
    <time_frame>Symptoms collected from Challenge dose (at least 28 days after dose 2) to discharge (at least 96 hours after challenge dose)</time_frame>
    <description>Viral AGE due to Norovirus GII.4 strain during the inpatient stay that meets clinical illness definition 1,2 or 3 and positive for infection as measured by fecal virus excretion detected by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) OR a 4-fold rise in Immunoglobulin G Enzyme-Linked Immunosorbent Assay (IgG ELISA) anti-GII.4 norovirus P particle antibody titer from pre-challenge (Within 2 weeks of Challenge Day 0) to post-challenge (Challenge Day 30). The clinical illness definitions are 1: diarrhea (defined as ≥ 3 loose or liquid stools OR &gt;400-600 grams of loose or liquid stools produced in any 24-hour period), 2: vomiting (defined as ≥ 2 vomiting episodes in any 24-hour period) or 3. One Vomiting episode plus any loose or liquid stool in any 24-hour period OR one vomiting episode plus at least 2 of the following 5 events: nausea, fever ≥99.7°F orally, abdominal cramps or pains, abdominal gurgling or bloating, or myalgia in any 24-hour period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Solicited Local Adverse Events Within 7 Days Post-Dose 1</measure>
    <time_frame>Within 7 days post-dose 1</time_frame>
    <description>Local Adverse Events included local injection site reactions/symptoms: pain, tenderness, redness, and swelling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Solicited Local Adverse Events Within 7 Days Post-Dose 2</measure>
    <time_frame>Within 7 days post-dose 2</time_frame>
    <description>Local Adverse Events included local injection site reactions/symptoms: pain, tenderness, redness, and swelling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Solicited Systemic Adverse Events Within 7 Days Post-Dose 1</measure>
    <time_frame>Within 7 days post-dose 1</time_frame>
    <description>Systemic signs or symptoms included: elevated daily oral temperature (fever), headache, fatigue, muscle aches, chills, joint aches and gastrointestinal symptoms of nausea, vomiting, diarrhea, abdominal cramps/pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Solicited Systemic Adverse Events Within 7 Days Post-Dose 2</measure>
    <time_frame>Within 7 days post-dose 2</time_frame>
    <description>Systemic signs or symptoms included: elevated fever, headache, fatigue, muscle aches, chills, joint aches and gastrointestinal symptoms of nausea, vomiting, diarrhea, abdominal cramps/pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs) 365 Days Following the Last Study Vaccination</measure>
    <time_frame>365 Days Following Dose 2 (Up to 393 days)</time_frame>
    <description>A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With 4-Fold Rise In Serum P-Particle Antibody Titer by ELISA or Detection of Norovirus GII.4 by RT-PCR in the Stool</measure>
    <time_frame>Pre Challenge to 30 Days Post Challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Viral AGE Due to GII.4 Strain Assessed by Modified Vesikari Scoring System During the Inpatient Phase</measure>
    <time_frame>Symptoms collected from Challenge dose (at least 28 days after dose 2) to discharge (at least 96 hours after challenge dose)</time_frame>
    <description>Vesikari Scoring System assesses the following symptoms: duration of diarrhea (days), maximum number of diarrheal stools/24 hours, duration of vomiting (days), maximum number of vomiting episodes/24 hours, fever and dehydration. Since the typical inpatient phase was four days in length, the duration of diarrhea scoring was modified to fit this time frame. Modified Vesikari Scale Total Score=0 to 17. Higher numbers are worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Viral AGE Due to GII.4 Strain Assessed by Post-Challenge Symptom Collection During the Inpatient Phase</measure>
    <time_frame>Symptoms collected from Challenge dose (at least 28 days after dose 2) to discharge (at least 96 hours after challenge dose)</time_frame>
    <description>Score 1 was based on a subset of symptoms including: elevated oral temperature, myalgia, nausea, abdominal cramps, bloating, diarrhea, and vomiting. Score 2 was based on all Score 1 symptoms plus fatigue/malaise, chills, and loss of appetite. Total Score 1=0 to 20 and Total Score 2=0 to 29. Higher numbers are worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Viral AGE Due to GII.4 Strain During the Inpatient Phase</measure>
    <time_frame>Symptoms collected from Challenge dose (at least 28 days after dose 2) to discharge (at least 96 hours after challenge dose)</time_frame>
    <description>Duration of symptoms was determined by a blinded committee review of each participant's symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With GII.4 Norovirus Positive RT-PCR in the Stool During the Inpatient and /or Outpatient Phase</measure>
    <time_frame>Pre Challenge to 30 Days Post Challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With GII.4 Seroresponse Rate (4-fold Rise) From Pre-challenge Day 0 to Post-Challenge Day 30</measure>
    <time_frame>Pre Challenge to 30 Days Post Challenge</time_frame>
    <description>Seroresponse was a 4-fold increase in IgG ELISA anti-GII.4 norovirus P particle antibody titer from pre-challenge to post-challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pan-Ig ELISA - Anti-Norovirus GI.1 VLP Geometric Mean Fold Rise (GMFR) From Baseline</measure>
    <time_frame>Baseline to 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pan-Ig ELISA - Anti-Norovirus GI.1 VLP Seroresponse (4-fold Rise) From Baseline</measure>
    <time_frame>Baseline, 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pan-Ig ELISA - Anti-Norovirus GI.1 VLP Geometric Mean Titer (GMT)</measure>
    <time_frame>Baseline, 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pan-Ig ELISA - Anti-Norovirus GII.4 cVLP GMFR From Baseline</measure>
    <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pan-Ig ELISA - Anti-Norovirus GII.4 cVLP Seroresponse From Baseline</measure>
    <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
    <description>Seroresponse was defined as a 4-Fold Rise from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pan-Ig ELISA - Anti-Norovirus GII.4 cVLP GMT</measure>
    <time_frame>Baseline, 28 days post Dose 1 and 28 days post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA Immunoglobulin A (IgA)- Anti-Norovirus GI.1 VLP Geometric Mean Fold Rise (GMFR) From Baseline</measure>
    <time_frame>Baseline to 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ELISA IgA- Anti-Norovirus GI.1 VLP Seroresponse (4-fold Rise) From Baseline</measure>
    <time_frame>Baseline to 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA IgA- Anti-Norovirus GI.1 VLP Geometric Mean Titer (GMT)</measure>
    <time_frame>Baseline, 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA IgA- Anti-Norovirus GII.4 cVLP GMFR From Baseline</measure>
    <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participant With ELISA IgA- Anti-Norovirus GII.4 cVLP Seroresponse From Baseline</measure>
    <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
    <description>Seroresponse was defined as a 4-Fold Rise from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA IgA- Anti-Norovirus GII.4 cVLP GMT</measure>
    <time_frame>Baseline, 28 days post Dose 1 and 28 days post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBGA (PGM) - Anti-Norovirus GI.1 VLP GMFR From Baseline</measure>
    <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
    <description>HBGA (PGM) is Histoblood Group Antigen (Pig Gastric Mucin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBGA (PGM) - Anti-Norovirus GI.1 VLP Seroresponse From Baseline</measure>
    <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
    <description>Seroresponse was defined as a 4-Fold Rise from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBGA (PGM) - Anti-Norovirus GI.1 VLP GMT</measure>
    <time_frame>Baseline, 28 days post Dose 1 and 28 days post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBGA (PGM) - Anti-Norovirus GII.4 cVLP GMFR From Baseline</measure>
    <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBGA (PGM) - Anti-Norovirus GII.4 cVLP Seroresponse From Baseline</measure>
    <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
    <description>Seroresponse was defined as a 4-Fold Rise from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBGA (PGM) - Anti-Norovirus GII.4 cVLP GMT</measure>
    <time_frame>Baseline, 28 days post Dose 1 and 28 days post Dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Unsolicited Non-Serious [i.e Other Than SAEs] Adverse Events (AEs)</measure>
    <time_frame>Vaccination Stage: Initial vaccination until 28 days after second vaccination; or Challenge Stage: the day of challenge until 60 days after challenge</time_frame>
    <description>Unsolicited AEs indicates any and all AEs that occurred other than those that were solicited.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of GII.4 Serum HBGA Antibodies Prior to Challenge Associated With Protection From GII.4 Illness</measure>
    <time_frame>Pre Challenge to Day 30 Post Challenge</time_frame>
    <description>Percentage of placebo subjects HBGA seropositive pre-challenge by illness status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of GII.4 Serum HGBA Antibodies Prior to Challenge Associated With Protection From GII.4 Infection</measure>
    <time_frame>Pre Challenge to Day 30 Post Challenge</time_frame>
    <description>Percentage of placebo subjects HBGA seropositive pre-challenge by infection status.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Prevention From Norovirus Infection</condition>
  <arm_group>
    <arm_group_label>Norovirus Bivalent VLP Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Placebo (0.9% sodium chloride (NaCl) and preservative-free), intramuscular (IM), Days 0 and 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Norovirus Bivalent Vaccine</intervention_name>
    <description>2 doses IM 28 days apart</description>
    <arm_group_label>Norovirus Bivalent VLP Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline Comparator</intervention_name>
    <description>2 doses IM 28 days apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible to participate in this study, a subject must meet the following criteria:

          1. Signed informed consent.

          2. Age 18 to 50 years (e.g., not reached their 50th birthday).

          3. Good general health as determined by a screening evaluation within 45 days of
             randomization.

          4. Expressed interest, availability, and understanding to fulfill the study requirements
             including measures to prevent Norovirus contamination of the environment and spread of
             infection and illness to the community. The prospective subjects must pass (≥70 %
             correct answers) a written examination on all aspects of the study before enrollment.

          5. Available to return for follow-up visits following discharge from the inpatient unit
             and able to deliver stool specimens to the investigative site promptly with no plan to
             move within the duration of the study.

          6. Female subjects must be of non-childbearing potential, or if of childbearing potential
             (as determined by the investigator) must be practicing abstinence or using an
             effective licensed method of birth control (e.g. oral contraceptives; diaphragm or
             condom in combination with contraceptive jelly, cream, or foam; intrauterine
             contraceptive device, or Depo-Provera; skin patch; vaginal ring or cervical cap) for
             30 days prior to vaccination and must agree to continue such precautions during the
             study and for 60 days after the Challenge visit. Male subjects must agree not to
             father a child from the day of vaccination until 60 days after the Challenge visit.

          7. Have a serum antibody titer of ≤1:1600 to the GII.4 Norovirus challenge strain as
             measured by Immunoglobulin G (IgG) P Particle Enzyme-Linked Immunosorbent Assay
             (ELISA.)

          8. Demonstrated to be H Type 1 secretor positive by Histoblood Group Antigen (HBGA)
             binding assay of their saliva test. [This saliva test may be done at anytime prior to
             enrollment and does not need to be repeated.]

          9. Negative serology for hepatitis C antibody, Human Immune Deficiency Virus (HIV)
             antibody, hepatitis B surface antigen, and Rapid Plasma Reagin (RPR).

         10. Agrees not to participate in another clinical trial with an investigational product
             for the duration of the study (12 months after the last dose of study vaccine or
             placebo i.e. 393 days).

        Exclusion Criteria:

        To be eligible to participate in this study, a subject must NOT meet any of the following
        criteria:

          1. Living with or having daily contact with children age 5 years or less or a woman known
             to be pregnant. This includes significant contact at home, school, day-care, or
             equivalent facilities.

          2. Nursing mother.

          3. Living with or having daily contact with childcare workers.

          4. Living with or having daily contact with elderly persons aged 70 years or more, or
             infirmed, diapered individuals, persons with disabilities or incontinent persons. This
             includes work or visits to nursing homes and day-care or equivalent facilities.

          5. History of any gastroenteritis suggestive of Norovirus illness since screening serum
             antibody IgG P Particle ELISA testing was done.

          6. History of any gastroenteritis within the past 2 weeks.

          7. History of chronic functional dyspepsia, chronic gastroesophageal reflux disease,
             peptic ulcer disease, gastrointestinal hemorrhage, gall bladder disease, inflammatory
             bowel disease, irritable bowel syndrome, frequent diarrhea, chronic constipation,
             malabsorption, maldigestion, major Gastrointestinal (GI) surgery, or diverticulitis
             anytime during the subject's lifetime or any other chronic GI disorders that would
             interfere with interpretation of symptoms or evaluation during the study.

          8. Routine use of medication other than oral contraceptive agents, anti-hypertensives,
             anti-depressants, vitamins and minerals. The use of any other medications should be
             discussed with the Sponsor and/or Central Safety Monitor (CSM).

          9. History of any of the following medical illnesses:

               -  Immunosuppression (disease or treatments that may affect immune system function)

               -  Diabetes (including gestational diabetes during the pregnancy that required
                  treatment other than dietary).

               -  Cancer (malignancy other than a resolved or excised skin lesion).

               -  Heart disease (hospitalization for a heart attack, arrhythmia, or syncope)

               -  Unconsciousness (other than a single brief &quot;concussion&quot;)

               -  Seizures (other than febrile seizures as a child &lt;5 years old)

               -  Asthma requiring treatment with inhaler or medication in the past 2 years.

               -  Neuro-inflammatory disease

               -  Autoimmune disease

               -  Eating disorder

               -  Chronic headaches associated with vomiting

               -  Chronic vomiting syndrome

         10. Any current illness requiring daily medication other than vitamins, minerals, birth
             control, anti-hypertensives or anti-depressants. The use of any other medications
             should be discussed with the Sponsor and/or CSM.

         11. Allergies or hypersensitivity to any component of the vaccine or challenge virus.

         12. Any clinically significant abnormality detected on physical examination, including:

               -  Murmur (other than a functional, ie normal, murmur)

               -  Focal neurological abnormality

               -  Hepatosplenomegaly

               -  Lymphadenopathy

               -  Jaundice

         13. Hypertension defined as BP &gt; 150/90 mm Hg on two separate measurements. Chronic stable
             well-controlled hypertension on medications is allowed.

         14. History of 3 or more hospitalizations for invasive bacterial infections (pneumonia,
             meningitis), acute or chronic dermatitis (e.g. eczema, seborrhea, psoriasis) or
             collagen vascular disease (e.g. Systemic Lupus Erythematosus (SLE) or
             dermatomyositis).

         15. Presence of serious chronic illness.

         16. Positive stool/fecal culture for bacterial pathogens (salmonella, campylobacter, E.
             coli 0157:H7, yersinia, or shigella) or positive stool/fecal screen for ova and
             parasites.

         17. Employment in the food service industry, such as restaurants or cafeteria facilities.
             Specifically, this will include persons whose employment requires food processing in
             the 4 weeks following challenge.

         18. Health-care workers with patient contact expected in the 4 weeks following challenge.

         19. Expected contact (through employment or at home) with immunocompromised persons
             (HIV-positive, receiving immunosuppressive medications such as oral steroids or
             anti-neoplastic agents) in the 4 weeks following challenge.

         20. Employment as an airline flight attendant scheduled to work in the 4 weeks following
             challenge.

         21. Persons planning on taking a cruise in the 4 weeks following challenge.

         22. Persons who plan to be living in a confined environment (e.g. ship, camp, or
             dormitory) within 4 weeks following challenge.

         23. Persons who have consumed or plan to consume raw shellfish (e.g. oysters) from
             screening through post challenge Day 30.

         24. Any of the following lab abnormalities (per the site local laboratory):

               -  Absolute neutrophil count (ANC) outside the normal range

               -  Total White Blood Cell Count (WBC) outside the normal range

               -  Hemoglobin or hematocrit outside the normal range

               -  Platelet count outside the normal range

               -  Electrolytes [Sodium (Na), Potassium (K), Chloride (Cl), Carbon dioxide (CO2)],
                  Blood Urea Nitrogen (BUN) and/or creatinine outside the normal range

               -  Screening glucose &gt; upper limit of normal (ULN). Fasting glucose is not required

               -  Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), alkaline
                  phosphatase, bilirubin (total and indirect), or Gamma Glutamyl Transferase (GGT)
                  outside the upper limit of the normal range

               -  Screening urinalysis with a value higher than &quot;trace&quot; positive for urine protein
                  or urine glucose, or urine Red Blood Cells (RBCs) (≥3; other than women during
                  menses).

             All of the above labs may be repeated if outside the normal limits. If repeated and
             continue outside site normal ranges, may enroll if determined by the Principal
             Investigator (PI) to be not clinically significant and discussed with the Sponsor
             and/or CSM.

         25. For women of child bearing potential, positive serum pregnancy test within 14 days or
             positive urine pregnancy test within one day of randomization.

         26. Temperature &gt; 100.4°F orally, or symptoms of an acute self-limited illness such as an
             upper respiratory infection within 3 days of administering either dose of Norovirus
             Bivalent VLP vaccine or placebo control or the challenge product.

         27. Resting heart rate &gt;100 beats per minute or &lt;55 beats per minute, respiratory rate ≥
             20 breaths per minute. If heart rate &lt;55 beat per minute and the investigator
             determines that this is not clinically significant and heart rate increases &gt; 55 beats
             per minute on moderate exercise, subject will not be excluded. Vital signs may be
             repeated.

         28. Clinically abnormal screening electrocardiogram (ECG) defined as pathologic Q waves
             and significant ST-T wave changes; criteria for left ventricular hypertrophy; and any
             non-sinus rhythm excluding isolated premature atrial contractions.

         29. Previous participation in a study of experimental norovirus infection or norovirus
             vaccine.

         30. Study site personnel or their family members

         31. Significant history of psychiatric hospitalization, alcohol abuse, or illicit drug
             use.

         32. Receipt of a licensed live vaccine within 28 days or a licensed inactivated vaccine
             within 14 days of administration of either dose of vaccine or placebo or the challenge
             product.

         33. Completion of an investigational vaccine or drug study within 7 days of randomization.

         34. Receipt of systemic corticosteroids for greater than 7 days within the past six
             months.

         35. Regular use of laxatives or anti-motility agents.

         36. Receipt of blood or blood products within the past six months.

         37. Subjects who are unwilling or unable to cease smoking from entry to the inpatient
             facility until discharge from the inpatient facility.

         38. Other condition that in the clinical judgment of the investigator would jeopardize the
             safety or rights of a subject participating in the trial, would render the subject
             unable to comply with the protocol, or would interfere with the evaluation of the
             Vaccination stage or the evaluation of the Challenge stage.

        Challenge Stage Exclusion Criteria

        The following additional exclusion criteria must not be met prior to admission to the
        inpatient unit for Challenge:

          1. Use of antibiotics within the 7 days prior to entry into the inpatient challenge
             facility.

          2. Use of any H-2 receptor antagonists (e.g. Tagamet, Zantac, and Pepcid), proton pump
             inhibitors (e.g. Prilosec, Protonix, and Prevacid), or prescription acid suppression
             medication or over the counter antacids within 72 hours of the challenge.

          3. Use of prescription or Over the Counter (OTC) medications containing acetaminophen,
             aspirin, ibuprofen, and/or other non-steroidal anti-inflammatory drugs within 48 hours
             prior to challenge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bernstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinatti Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed S Al-Ibrahim, MB, ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNBL Clinical Pharmacology Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Y Graham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert L Atmar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Marshall Lyon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John J Treanor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SNBL</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3498</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, Vinjé J, Gregoricus N, Frenck RW Jr, Moe CL, Al-Ibrahim MS, Barrett J, Ferreira J, Estes MK, Graham DY, Goodwin R, Borkowski A, Clemens R, Mendelman PM. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis. 2015 Mar 15;211(6):870-8. doi: 10.1093/infdis/jiu497. Epub 2014 Sep 9.</citation>
    <PMID>25210140</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <results_first_submitted>December 8, 2015</results_first_submitted>
  <results_first_submitted_qc>July 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2016</results_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 5 investigative sites in the United States from 16 June 2012 to 18 March 2014.</recruitment_details>
      <pre_assignment_details>Healthy Volunteers were enrolled equally in 1 of 2 treatment groups, Norovirus Bivalent VLP Vaccine or Placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Norovirus Bivalent VLP Vaccine</title>
          <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 2 Doses</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Challenge Product</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance/Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Norovirus Bivalent VLP Vaccine</title>
          <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="132"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" spread="10.2"/>
                    <measurement group_id="B2" value="32.1" spread="9.3"/>
                    <measurement group_id="B3" value="32.4" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian/Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Viral AGE Clinical Illness and Fecal Virus Excretion Detected by RT-PCR OR 4-Fold Rise In Anti-GII.4 Norovirus P Particle Antibody Titer</title>
        <description>Viral AGE due to Norovirus GII.4 strain during the inpatient stay that meets clinical illness definition 1,2 or 3 and positive for infection as measured by fecal virus excretion detected by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) OR a 4-fold rise in Immunoglobulin G Enzyme-Linked Immunosorbent Assay (IgG ELISA) anti-GII.4 norovirus P particle antibody titer from pre-challenge (Within 2 weeks of Challenge Day 0) to post-challenge (Challenge Day 30). The clinical illness definitions are 1: diarrhea (defined as ≥ 3 loose or liquid stools OR &gt;400-600 grams of loose or liquid stools produced in any 24-hour period), 2: vomiting (defined as ≥ 2 vomiting episodes in any 24-hour period) or 3. One Vomiting episode plus any loose or liquid stool in any 24-hour period OR one vomiting episode plus at least 2 of the following 5 events: nausea, fever ≥99.7°F orally, abdominal cramps or pains, abdominal gurgling or bloating, or myalgia in any 24-hour period.</description>
        <time_frame>Symptoms collected from Challenge dose (at least 28 days after dose 2) to discharge (at least 96 hours after challenge dose)</time_frame>
        <population>Modified intent-to-treat population (mITT) included all participants who received at least one dose of study drug, challenge stage.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Viral AGE Clinical Illness and Fecal Virus Excretion Detected by RT-PCR OR 4-Fold Rise In Anti-GII.4 Norovirus P Particle Antibody Titer</title>
          <description>Viral AGE due to Norovirus GII.4 strain during the inpatient stay that meets clinical illness definition 1,2 or 3 and positive for infection as measured by fecal virus excretion detected by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) OR a 4-fold rise in Immunoglobulin G Enzyme-Linked Immunosorbent Assay (IgG ELISA) anti-GII.4 norovirus P particle antibody titer from pre-challenge (Within 2 weeks of Challenge Day 0) to post-challenge (Challenge Day 30). The clinical illness definitions are 1: diarrhea (defined as ≥ 3 loose or liquid stools OR &gt;400-600 grams of loose or liquid stools produced in any 24-hour period), 2: vomiting (defined as ≥ 2 vomiting episodes in any 24-hour period) or 3. One Vomiting episode plus any loose or liquid stool in any 24-hour period OR one vomiting episode plus at least 2 of the following 5 events: nausea, fever ≥99.7°F orally, abdominal cramps or pains, abdominal gurgling or bloating, or myalgia in any 24-hour period.</description>
          <population>Modified intent-to-treat population (mITT) included all participants who received at least one dose of study drug, challenge stage.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.674</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing Solicited Local Adverse Events Within 7 Days Post-Dose 1</title>
        <description>Local Adverse Events included local injection site reactions/symptoms: pain, tenderness, redness, and swelling.</description>
        <time_frame>Within 7 days post-dose 1</time_frame>
        <population>MITT population included all participants who received at least one dose of study drug. Data is missing for 2 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Solicited Local Adverse Events Within 7 Days Post-Dose 1</title>
          <description>Local Adverse Events included local injection site reactions/symptoms: pain, tenderness, redness, and swelling.</description>
          <population>MITT population included all participants who received at least one dose of study drug. Data is missing for 2 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="54.0" upper_limit="77.8"/>
                    <measurement group_id="O2" value="28.1" lower_limit="17.6" upper_limit="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing Solicited Local Adverse Events Within 7 Days Post-Dose 2</title>
        <description>Local Adverse Events included local injection site reactions/symptoms: pain, tenderness, redness, and swelling.</description>
        <time_frame>Within 7 days post-dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, who received a second dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Solicited Local Adverse Events Within 7 Days Post-Dose 2</title>
          <description>Local Adverse Events included local injection site reactions/symptoms: pain, tenderness, redness, and swelling.</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, who received a second dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0" lower_limit="40.9" upper_limit="66.6"/>
                    <measurement group_id="O2" value="20.6" lower_limit="11.5" upper_limit="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing Solicited Systemic Adverse Events Within 7 Days Post-Dose 1</title>
        <description>Systemic signs or symptoms included: elevated daily oral temperature (fever), headache, fatigue, muscle aches, chills, joint aches and gastrointestinal symptoms of nausea, vomiting, diarrhea, abdominal cramps/pain.</description>
        <time_frame>Within 7 days post-dose 1</time_frame>
        <population>MITT included all participants who received at least one dose of study drug. Data is missing for 2 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Solicited Systemic Adverse Events Within 7 Days Post-Dose 1</title>
          <description>Systemic signs or symptoms included: elevated daily oral temperature (fever), headache, fatigue, muscle aches, chills, joint aches and gastrointestinal symptoms of nausea, vomiting, diarrhea, abdominal cramps/pain.</description>
          <population>MITT included all participants who received at least one dose of study drug. Data is missing for 2 participants.</population>
          <units>percentage of particpants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="24.9" upper_limit="49.1"/>
                    <measurement group_id="O2" value="32.8" lower_limit="21.6" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing Solicited Systemic Adverse Events Within 7 Days Post-Dose 2</title>
        <description>Systemic signs or symptoms included: elevated fever, headache, fatigue, muscle aches, chills, joint aches and gastrointestinal symptoms of nausea, vomiting, diarrhea, abdominal cramps/pain.</description>
        <time_frame>Within 7 days post-dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, who received a second dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Solicited Systemic Adverse Events Within 7 Days Post-Dose 2</title>
          <description>Systemic signs or symptoms included: elevated fever, headache, fatigue, muscle aches, chills, joint aches and gastrointestinal symptoms of nausea, vomiting, diarrhea, abdominal cramps/pain.</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, who received a second dose.</population>
          <units>percentage of particpants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="19.2" upper_limit="43.0"/>
                    <measurement group_id="O2" value="19.0" lower_limit="10.2" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serious Adverse Events (SAEs) 365 Days Following the Last Study Vaccination</title>
        <description>A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
        <time_frame>365 Days Following Dose 2 (Up to 393 days)</time_frame>
        <population>MITT population included all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events (SAEs) 365 Days Following the Last Study Vaccination</title>
          <description>A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
          <population>MITT population included all participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With 4-Fold Rise In Serum P-Particle Antibody Titer by ELISA or Detection of Norovirus GII.4 by RT-PCR in the Stool</title>
        <time_frame>Pre Challenge to 30 Days Post Challenge</time_frame>
        <population>MITT population included all participants who received at least one dose of study drug, Challenge stage.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 4-Fold Rise In Serum P-Particle Antibody Titer by ELISA or Detection of Norovirus GII.4 by RT-PCR in the Stool</title>
          <population>MITT population included all participants who received at least one dose of study drug, Challenge stage.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RT-PCR Alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Fold rise in P-particle ELISA alone; n=56,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Either RT-PCR or 4-fold rise in P-particle;n=56,52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Viral AGE Due to GII.4 Strain Assessed by Modified Vesikari Scoring System During the Inpatient Phase</title>
        <description>Vesikari Scoring System assesses the following symptoms: duration of diarrhea (days), maximum number of diarrheal stools/24 hours, duration of vomiting (days), maximum number of vomiting episodes/24 hours, fever and dehydration. Since the typical inpatient phase was four days in length, the duration of diarrhea scoring was modified to fit this time frame. Modified Vesikari Scale Total Score=0 to 17. Higher numbers are worse.</description>
        <time_frame>Symptoms collected from Challenge dose (at least 28 days after dose 2) to discharge (at least 96 hours after challenge dose)</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, challenge stage with Viral AGE.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Viral AGE Due to GII.4 Strain Assessed by Modified Vesikari Scoring System During the Inpatient Phase</title>
          <description>Vesikari Scoring System assesses the following symptoms: duration of diarrhea (days), maximum number of diarrheal stools/24 hours, duration of vomiting (days), maximum number of vomiting episodes/24 hours, fever and dehydration. Since the typical inpatient phase was four days in length, the duration of diarrhea scoring was modified to fit this time frame. Modified Vesikari Scale Total Score=0 to 17. Higher numbers are worse.</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, challenge stage with Viral AGE.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.0"/>
                    <measurement group_id="O2" value="7.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Statistically significant at p&lt;0.05. No multiplicity adjustment.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Viral AGE Due to GII.4 Strain Assessed by Post-Challenge Symptom Collection During the Inpatient Phase</title>
        <description>Score 1 was based on a subset of symptoms including: elevated oral temperature, myalgia, nausea, abdominal cramps, bloating, diarrhea, and vomiting. Score 2 was based on all Score 1 symptoms plus fatigue/malaise, chills, and loss of appetite. Total Score 1=0 to 20 and Total Score 2=0 to 29. Higher numbers are worse.</description>
        <time_frame>Symptoms collected from Challenge dose (at least 28 days after dose 2) to discharge (at least 96 hours after challenge dose)</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, challenge stage with Viral AGE.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Viral AGE Due to GII.4 Strain Assessed by Post-Challenge Symptom Collection During the Inpatient Phase</title>
          <description>Score 1 was based on a subset of symptoms including: elevated oral temperature, myalgia, nausea, abdominal cramps, bloating, diarrhea, and vomiting. Score 2 was based on all Score 1 symptoms plus fatigue/malaise, chills, and loss of appetite. Total Score 1=0 to 20 and Total Score 2=0 to 29. Higher numbers are worse.</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, challenge stage with Viral AGE.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Score 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.0"/>
                    <measurement group_id="O2" value="3.3" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.5"/>
                    <measurement group_id="O2" value="4.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Score 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>Statistically significant at p&lt;0.05. No multiplicity adjustment.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Score 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <p_value_desc>Statistically significant at p&lt;0.05. No multiplicity adjustment.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Viral AGE Due to GII.4 Strain During the Inpatient Phase</title>
        <description>Duration of symptoms was determined by a blinded committee review of each participant's symptoms.</description>
        <time_frame>Symptoms collected from Challenge dose (at least 28 days after dose 2) to discharge (at least 96 hours after challenge dose)</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, challenge stage with Viral AGE.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Viral AGE Due to GII.4 Strain During the Inpatient Phase</title>
          <description>Duration of symptoms was determined by a blinded committee review of each participant's symptoms.</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, challenge stage with Viral AGE.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" lower_limit="10.4" upper_limit="60.0"/>
                    <measurement group_id="O2" value="38.0" lower_limit="2.0" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.199</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With GII.4 Norovirus Positive RT-PCR in the Stool During the Inpatient and /or Outpatient Phase</title>
        <time_frame>Pre Challenge to 30 Days Post Challenge</time_frame>
        <population>Participants from the MITT population, all participants with at least one dose of study drug, challenge stage with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With GII.4 Norovirus Positive RT-PCR in the Stool During the Inpatient and /or Outpatient Phase</title>
          <population>Participants from the MITT population, all participants with at least one dose of study drug, challenge stage with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (n=54,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n=52,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=55,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                    <measurement group_id="O2" value="51.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n=52,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2"/>
                    <measurement group_id="O2" value="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10 (n=55,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (n=56,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Day 1 to 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Any Day 1 to 30</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.562</p_value>
            <p_value_desc>Comparison of % Positive</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With GII.4 Seroresponse Rate (4-fold Rise) From Pre-challenge Day 0 to Post-Challenge Day 30</title>
        <description>Seroresponse was a 4-fold increase in IgG ELISA anti-GII.4 norovirus P particle antibody titer from pre-challenge to post-challenge.</description>
        <time_frame>Pre Challenge to 30 Days Post Challenge</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With GII.4 Seroresponse Rate (4-fold Rise) From Pre-challenge Day 0 to Post-Challenge Day 30</title>
          <description>Seroresponse was a 4-fold increase in IgG ELISA anti-GII.4 norovirus P particle antibody titer from pre-challenge to post-challenge.</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="2.0" upper_limit="17.3"/>
                    <measurement group_id="O2" value="52.9" lower_limit="38.5" upper_limit="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of GII.4 Serum HBGA Antibodies Prior to Challenge Associated With Protection From GII.4 Illness</title>
        <description>Percentage of placebo subjects HBGA seropositive pre-challenge by illness status.</description>
        <time_frame>Pre Challenge to Day 30 Post Challenge</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo_Not Ill</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of GII.4 Serum HBGA Antibodies Prior to Challenge Associated With Protection From GII.4 Illness</title>
          <description>Percentage of placebo subjects HBGA seropositive pre-challenge by illness status.</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of GII.4 Serum HGBA Antibodies Prior to Challenge Associated With Protection From GII.4 Infection</title>
        <description>Percentage of placebo subjects HBGA seropositive pre-challenge by infection status.</description>
        <time_frame>Pre Challenge to Day 30 Post Challenge</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo_Not Infected</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of GII.4 Serum HGBA Antibodies Prior to Challenge Associated With Protection From GII.4 Infection</title>
          <description>Percentage of placebo subjects HBGA seropositive pre-challenge by infection status.</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pan-Ig ELISA - Anti-Norovirus GI.1 VLP Geometric Mean Fold Rise (GMFR) From Baseline</title>
        <time_frame>Baseline to 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Pan-Ig ELISA - Anti-Norovirus GI.1 VLP Geometric Mean Fold Rise (GMFR) From Baseline</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" lower_limit="47" upper_limit="91"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n= 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" lower_limit="43.9" upper_limit="85.2"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.8" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pan-Ig ELISA - Anti-Norovirus GI.1 VLP Seroresponse (4-fold Rise) From Baseline</title>
        <time_frame>Baseline, 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pan-Ig ELISA - Anti-Norovirus GI.1 VLP Seroresponse (4-fold Rise) From Baseline</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n= 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="3.4" lower_limit="0.4" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pan-Ig ELISA - Anti-Norovirus GI.1 VLP Geometric Mean Titer (GMT)</title>
        <time_frame>Baseline, 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Pan-Ig ELISA - Anti-Norovirus GI.1 VLP Geometric Mean Titer (GMT)</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-Dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1857.6" lower_limit="1314.1" upper_limit="2626.0"/>
                    <measurement group_id="O2" value="1671.1" lower_limit="1188.9" upper_limit="2348.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127209.7" lower_limit="99321.5" upper_limit="162928.4"/>
                    <measurement group_id="O2" value="1577.6" lower_limit="1105.5" upper_limit="2251.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120552.8" lower_limit="98844.3" upper_limit="147029.0"/>
                    <measurement group_id="O2" value="1606.3" lower_limit="1097.7" upper_limit="2350.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pan-Ig ELISA - Anti-Norovirus GII.4 cVLP GMFR From Baseline</title>
        <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Pan-Ig ELISA - Anti-Norovirus GII.4 cVLP GMFR From Baseline</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="8.3" upper_limit="17.9"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="7.5" upper_limit="14.5"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.9" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pan-Ig ELISA - Anti-Norovirus GII.4 cVLP Seroresponse From Baseline</title>
        <description>Seroresponse was defined as a 4-Fold Rise from Baseline.</description>
        <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pan-Ig ELISA - Anti-Norovirus GII.4 cVLP Seroresponse From Baseline</title>
          <description>Seroresponse was defined as a 4-Fold Rise from Baseline.</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" lower_limit="70.9" upper_limit="90.9"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5" lower_limit="77.8" upper_limit="95.3"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.0" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pan-Ig ELISA - Anti-Norovirus GII.4 cVLP GMT</title>
        <time_frame>Baseline, 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Pan-Ig ELISA - Anti-Norovirus GII.4 cVLP GMT</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-Dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5120.0" lower_limit="3754.9" upper_limit="6981.3"/>
                    <measurement group_id="O2" value="4958.8" lower_limit="3776.8" upper_limit="6510.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63604.8" lower_limit="49961.2" upper_limit="80974.3"/>
                    <measurement group_id="O2" value="4845.9" lower_limit="3640.0" upper_limit="6451.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56303.8" lower_limit="45918.6" upper_limit="69037.7"/>
                    <measurement group_id="O2" value="5306.9" lower_limit="3822.1" upper_limit="7368.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA Immunoglobulin A (IgA)- Anti-Norovirus GI.1 VLP Geometric Mean Fold Rise (GMFR) From Baseline</title>
        <time_frame>Baseline to 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA Immunoglobulin A (IgA)- Anti-Norovirus GI.1 VLP Geometric Mean Fold Rise (GMFR) From Baseline</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="11.5" upper_limit="23.2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n= 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="8.2" upper_limit="16.2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ELISA IgA- Anti-Norovirus GI.1 VLP Seroresponse (4-fold Rise) From Baseline</title>
        <time_frame>Baseline to 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ELISA IgA- Anti-Norovirus GI.1 VLP Seroresponse (4-fold Rise) From Baseline</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="74.6" upper_limit="93.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n= 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" lower_limit="68.2" upper_limit="89.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA IgA- Anti-Norovirus GI.1 VLP Geometric Mean Titer (GMT)</title>
        <time_frame>Baseline, 28 days Post Dose 1 and 28 days Post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA IgA- Anti-Norovirus GI.1 VLP Geometric Mean Titer (GMT)</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-Dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.5" upper_limit="4.8"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.5" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" lower_limit="46.8" upper_limit="95.7"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.5" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" lower_limit="33.2" upper_limit="67.8"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.5" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA IgA- Anti-Norovirus GII.4 cVLP GMFR From Baseline</title>
        <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA IgA- Anti-Norovirus GII.4 cVLP GMFR From Baseline</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="6.7" upper_limit="12.1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="6.0" upper_limit="9.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participant With ELISA IgA- Anti-Norovirus GII.4 cVLP Seroresponse From Baseline</title>
        <description>Seroresponse was defined as a 4-Fold Rise from Baseline.</description>
        <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participant With ELISA IgA- Anti-Norovirus GII.4 cVLP Seroresponse From Baseline</title>
          <description>Seroresponse was defined as a 4-Fold Rise from Baseline.</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" lower_limit="60.3" upper_limit="83.4"/>
                    <measurement group_id="O2" value="3.2" lower_limit="0.4" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" lower_limit="59.2" upper_limit="82.9"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.0" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA IgA- Anti-Norovirus GII.4 cVLP GMT</title>
        <time_frame>Baseline, 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA IgA- Anti-Norovirus GII.4 cVLP GMT</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-Dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="4.8" upper_limit="7.4"/>
                    <measurement group_id="O2" value="5.8" lower_limit="4.8" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" lower_limit="43.3" upper_limit="67.6"/>
                    <measurement group_id="O2" value="6.1" lower_limit="5.0" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0" lower_limit="39.1" upper_limit="56.5"/>
                    <measurement group_id="O2" value="6.2" lower_limit="5.0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBGA (PGM) - Anti-Norovirus GI.1 VLP GMFR From Baseline</title>
        <description>HBGA (PGM) is Histoblood Group Antigen (Pig Gastric Mucin).</description>
        <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>HBGA (PGM) - Anti-Norovirus GI.1 VLP GMFR From Baseline</title>
          <description>HBGA (PGM) is Histoblood Group Antigen (Pig Gastric Mucin).</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="19.1" upper_limit="34.3"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="25.8" upper_limit="39.1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBGA (PGM) - Anti-Norovirus GI.1 VLP Seroresponse From Baseline</title>
        <description>Seroresponse was defined as a 4-Fold Rise from Baseline</description>
        <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBGA (PGM) - Anti-Norovirus GI.1 VLP Seroresponse From Baseline</title>
          <description>Seroresponse was defined as a 4-Fold Rise from Baseline</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2" lower_limit="86.7" upper_limit="99.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBGA (PGM) - Anti-Norovirus GI.1 VLP GMT</title>
        <time_frame>Baseline, 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>HBGA (PGM) - Anti-Norovirus GI.1 VLP GMT</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-Dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="14.6" upper_limit="20.9"/>
                    <measurement group_id="O2" value="15.2" lower_limit="13.2" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456.2" lower_limit="324.4" upper_limit="641.6"/>
                    <measurement group_id="O2" value="15.4" lower_limit="13.5" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573.5" lower_limit="453.0" upper_limit="726.1"/>
                    <measurement group_id="O2" value="15.1" lower_limit="13.1" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBGA (PGM) - Anti-Norovirus GII.4 cVLP GMFR From Baseline</title>
        <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>HBGA (PGM) - Anti-Norovirus GII.4 cVLP GMFR From Baseline</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="6.2" upper_limit="10.3"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="5.3" upper_limit="8.1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBGA (PGM) - Anti-Norovirus GII.4 cVLP Seroresponse From Baseline</title>
        <description>Seroresponse was defined as a 4-Fold Rise from Baseline.</description>
        <time_frame>Baseline to 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBGA (PGM) - Anti-Norovirus GII.4 cVLP Seroresponse From Baseline</title>
          <description>Seroresponse was defined as a 4-Fold Rise from Baseline.</description>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" lower_limit="57.0" upper_limit="80.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="60.9" upper_limit="84.2"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.0" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBGA (PGM) - Anti-Norovirus GII.4 cVLP GMT</title>
        <time_frame>Baseline, 28 days post Dose 1 and 28 days post Dose 2</time_frame>
        <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>HBGA (PGM) - Anti-Norovirus GII.4 cVLP GMT</title>
          <population>Participants from the MITT population, all participants who received at least one dose of study drug, with data available for analysis.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-Dose 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.2" lower_limit="104.8" upper_limit="135.5"/>
                    <measurement group_id="O2" value="127.5" lower_limit="109.5" upper_limit="148.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 1 (n=63, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="971.5" lower_limit="794.2" upper_limit="1188.3"/>
                    <measurement group_id="O2" value="126.4" lower_limit="107.7" upper_limit="148.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days Post Dose 2 (n=61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="803.0" lower_limit="679.8" upper_limit="948.7"/>
                    <measurement group_id="O2" value="136.7" lower_limit="113.3" upper_limit="165.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Unsolicited Non-Serious [i.e Other Than SAEs] Adverse Events (AEs)</title>
        <description>Unsolicited AEs indicates any and all AEs that occurred other than those that were solicited.</description>
        <time_frame>Vaccination Stage: Initial vaccination until 28 days after second vaccination; or Challenge Stage: the day of challenge until 60 days after challenge</time_frame>
        <population>MITT population included all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Norovirus Bivalent VLP Vaccine</title>
            <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Unsolicited Non-Serious [i.e Other Than SAEs] Adverse Events (AEs)</title>
          <description>Unsolicited AEs indicates any and all AEs that occurred other than those that were solicited.</description>
          <population>MITT population included all participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="4.3" upper_limit="20.3"/>
                    <measurement group_id="O2" value="23.1" lower_limit="13.5" upper_limit="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Dose 2 (n=63, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="6.7" upper_limit="25.4"/>
                    <measurement group_id="O2" value="18.8" lower_limit="10.1" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Challenge Stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" lower_limit="26.5" upper_limit="53.2"/>
                    <measurement group_id="O2" value="50.9" lower_limit="36.8" upper_limit="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events: 393 Days. Non-Serious Unsolicited Events Post Vaccination: Initial vaccination until 28 days after second vaccination</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Norovirus Bivalent VLP Vaccine</title>
          <description>Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Saline (0.9% NaCl and preservative-free), IM, Days 0 and 28.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

